MedTrace Logo

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

NCT00942968 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2024-04-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.

Conditions

Interventions

DRUG

dalteparin

Daily subcutaneous injection 200IU/kg dalteparin

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

  • Gary Palmer, MD · Medical Affairs, Eisai, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-03-31
Completion
2013-06-30

Countries

  • United States
  • Austria
  • Canada
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00942968 on ClinicalTrials.gov